<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875611</url>
  </required_header>
  <id_info>
    <org_study_id>20-NIO-0003</org_study_id>
    <nct_id>NCT04875611</nct_id>
  </id_info>
  <brief_title>Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment</brief_title>
  <acronym>NIVONASO-21</acronym>
  <official_title>Phase II Study Evaluating the Efficacy of Nivolumab in the Treatment of Patients With Nasopharyngeal Cancer Who Progressed During or After Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in&#xD;
      treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy&#xD;
      . Patients disqualified from radical therapy . The total number of patients was estimated for&#xD;
      32.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of objective responses (partial and complete responses combined /partial response (PR)+ complete response(CR)/ by immune Response Evaluation Criteria in Solid Tumours (iRECIST) response criteria) in MRI (Magnetic Resonance Imaging) after 12 weeks.&#xD;
Partial response - at least a 30% decrease in the sum of the LD(longest diameter) of target lesions, taking as reference the baseline sum LD(longest diameter)&#xD;
Complete response (CR)- disappearance of all target lesions and short dimension of all lymph nodes &lt; 10 mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.Progression- free survival (PFS) by iRECIST( immune Response Evaluation Criteria in Solid Tumours) criteria- from the beginning of treatment to the progression of disease or death.</measure>
    <time_frame>6 month of treatment phase</time_frame>
    <description>Progression will be evaluated in MRI(Magnetic Resonance Imaging) and defined according to iRECIST(immune Response Evaluation Criteria in Solid Tumours) criteria:&#xD;
least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the sum must also demonstrate an absolute increase of at least 5 mm.&#xD;
the appearance of one or more new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate- time of total survival</measure>
    <time_frame>at 6 months (treatment phase), 12 months and 18 months (6th month and 12th month of long term follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR(disease control rate) per RECIST (Response Evaluation Criteria in Solid Tumours)</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Defined as not meeting the criteria for progression and PR(partial response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR(duration of response) per RECIST (Response Evaluation Criteria in Solid Tumours)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Measured in MRI(Magnetic Resonance Imaging) from the time when measurement criteria for complete/ partial response are met till time when progression of the disease is documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life in EORTC QLQ-C30(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) (version 3.0) .A high scale score represents a higher response level.</measure>
    <time_frame>from first infusion to last follow up ( 3 month, 6 month, 9 month,12month follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment of treatment with Nivolumab measured by excesive toxity</measure>
    <time_frame>Each visit during treatment phase -12 cycles of investigation product's infusion (around 6 month of treatment).</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Nasopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental therapy:OPDIVO (Nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opdivo</intervention_name>
    <description>Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).</description>
    <arm_group_label>Experimental therapy:OPDIVO (Nivolumab)</arm_group_label>
    <other_name>Nivolumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years old&#xD;
&#xD;
          2. Histological or cytological documentation of squamous cell carcinoma.&#xD;
&#xD;
          3. Primary tumor location in nasopharynx&#xD;
&#xD;
          4. Previous, documented failure on platinum-based chemotherapy or progression of the&#xD;
             disease during platinum-based chemotherapy&#xD;
&#xD;
          5. Tumor recurrence (local or nodal) or generalization (metastasis) occurence during or&#xD;
             within 6 months after previous platinum-based chemotherapy&#xD;
&#xD;
          6. ECOG(Eastern Cooperative Oncology Group) performance scale 0-1&#xD;
&#xD;
          7. Participant is willing and able to give informed consent for participation in the&#xD;
             study and agrees to undergo all follow up visit and planned procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known active central nervous system metastases.&#xD;
&#xD;
          2. Presence of renal insufficiency defined as eGFR(estimated glomerular filtration rate)&#xD;
             &lt; 30 ml/min/m2&#xD;
&#xD;
          3. Presence of liver disfunction, defined as level of AST(aspartate aminotransferase) and&#xD;
             /or ALT(alanine aminotransferase) &gt; 2,5 x ULN(upper limits of normal) (&gt; 5 x ULN in&#xD;
             patients with documented liver metastases); total bilirubin &gt; 1,5 xULN ( bilirubin &gt;&#xD;
             1,5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is &lt; 35%) or&#xD;
             albumin &lt; 2,5 g/dL&#xD;
&#xD;
          4. Abnormalities in blood count such as: hemoglobin &lt; 9 g/dl, platelets &lt; 100 x 109 /L,&#xD;
             Absolute Neutrophil Count (ANC) &lt;1,0 x 109 /L&#xD;
&#xD;
          5. Ejection fraction in echocardiography &lt; 50%&#xD;
&#xD;
          6. History of active autoimmune diseases except for type I diabetes, hypothyroidism&#xD;
             (treated only with hormone supplementation), psoriasis, albinism.&#xD;
&#xD;
          7. Patient with diagnosed mental disorder preventing, in Investigator's opinion, from&#xD;
             participating in a clinical trial.&#xD;
&#xD;
          8. Pregnancy or breastfeeding.&#xD;
&#xD;
          9. Female with childbearing potential or male participant with female partner of&#xD;
             childbearing potential, who is unwilling or unable to use an acceptable method of&#xD;
             contraception to avoid pregnancy throughout the entire clinical trial period and for 5&#xD;
             months after the end of treatment (last infusion)&#xD;
&#xD;
         10. Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent&#xD;
&#xD;
         11. Patient is currently participating in another clinical trial.&#xD;
&#xD;
         12. Active infection, which significantly affects the patient's clinical condition and&#xD;
             requires treatment.&#xD;
&#xD;
         13. Patient with prior bone marrow or solid organ transplantation.&#xD;
&#xD;
         14. Patient requires immunosuppressive agents, including steroids (daily dose of&#xD;
             prednisone or equivalent &gt; 10 mg)&#xD;
&#xD;
         15. Known immunodeficiency including HIV/AIDS(human immunodeficiency virus/acquired&#xD;
             immunodeficiency syndrome) infection.&#xD;
&#xD;
         16. Patient received any live vaccine within 28 days before enrollment.&#xD;
&#xD;
         17. Heart Failure - NYHA(New York Heart Association functional classification system) III&#xD;
             or IV&#xD;
&#xD;
         18. Coexistence of active malignant tumor or history of malignant tumor after radical&#xD;
             treatment with disease-free period &gt; 2 years, except: cervical cancer in situ/&#xD;
             basocellular skin cancer/prostate cancer, after radical treatment.&#xD;
&#xD;
         19. Other comorbidities symptoms or conditions that in Investigator's judgement prevent&#xD;
             patient from participation in clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego Szpitala Klinicznego w Białymstoku</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ewa Sierko, dr hab.n. med.</last_name>
      <email>esierko@onkologia.bialystok.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii Gdańskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Rafał Dziadziuszko, Prof.dr hab.n.med.</last_name>
      <email>rafald@gumed.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Tomasz Rutkowski, Dr hab. n.med.</last_name>
      <email>Tomasz.rutkowski@io.gliwice.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantacji Szpiku, Świętokrzyskie Centrum Onkologii</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Piotr Kędzierawski, dr n. med.</last_name>
      <email>piotrkedzierawski@wp.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

